Adrenal InsufficiencyultradianNCT02934399
Dynamic Hormone Diagnostics in Endocrine Disease
An observational study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia, run by Haukeland University Hospital at 4 sites in 4 countries.
Trial summary
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary Hyperaldosteronism during conventional diagnostic and therapeutic follow-up. Read more about this study
- Who is it for?
- Ages 18 to 68 yearsHealthy volunteers can take part
- Conditions the study is for
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome
- What is being tested?
- 27 hour subcutaneous fluid sampling
- Type of treatment
- Injection or infusion
- How many people
- 528 participants
- Where
- 4 sitesin 4 countries
- Study dates
- Oct 2016to 14 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 68 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy Controls and patients with established Cushing syndrome, Adrenal Insufficiency, Congenital adrenal hyperplasia, Primary hyperaldosteronism, Acromegaly and Growth hormone deficiency
Who may be able to join
- Healthy male and female subjects aged 18-68 years, non-smokers or regular smokers of greater than 6 cigarettes a day, BMI 16-29
- Male and female Cushing's syndrome aged 18-68 years with biochemically confirmed based on cortisol and ACTH measurements, dexamethasone suppression test and 1 of the following positive investigations (24 hour urine cortisol, salivary/serum cortisol profile). Visible tumour in the pituitary and/or one of the following positive tests pointing to pituitary source for ACTH overproduction (bilateral petrosal sinus sampling, corticotropin releasing hormone test, high dose dexamethasone suppression test) or adrenal tumour considered fit for surgery. No contraceptives for 6 weeks prior to sampling (females only). Patients on medical therapy e.g. metyrapone for Cushings to have a 2 week washout off treatment prior to sampling
- Male and female aged 18 -68 years with biochemically confirmed adrenal insufficiency based on basal cortisol and ACTH measurements and/or Synacthen test +/- adrenal antibodies, and on oral hydrocortisone or cortisone acetate glucocorticoid replacement therapy
- Female aged 18-68 years with biochemically confirmed salt-wasting or simple virilising CAH based on 17OHP, cortisol, androgen, renin and ACTH measurements; disease causing mutation in CYP21A2 and/or synacthen testing.
- Male and female subjects aged 18 -68 years with biochemical confirmation of PHA based on a valid pathological aldosterone/renin ratio and non-suppressible aldosterone levels on one of the currently used confirmatory tests (saline/oral fludrocortisone test). Unilateral only - diagnostic CT and/or adrenal vein sampling
- Male and female subjects aged 18-68 years with biochemically confirmed GHD (arginine growth hormone releasing hormone test, insulin tolerance test, known pituitary disease with confirmed pan hypopituitarism)
- Male and female aged 18-68 years with biochemically confirmed acromegaly (oral glucose tolerance test or GH day curve and diagnostic insulin growth factor 1 levels) with radiological evidence of a pituitary adenoma.
Who cannot join
- Healthy controls undergoing or planning pregnancy or lactating women. Presence of any unstable pathological condition in past 3 months. On any regular prescribed medications (except contraception). Prior or current history of an endocrine disorder. Known allergy to Lignocaine, plasters. Current or past steroid therapies (oral, inhaled, parenteral or topical) or other interfering medication in last 3 months. Regular alcohol intake great then 26units of alcohol per week.Taking of any investigational drug within the past two months. Abuse of illicit drugs. Occasional smokers of cigarettes not able to abstain for sampling period or smoking less than 6 cigarettes a day. Needle phobia. Interfering diet/over the counter herbal remedies in last 14 days.
- Cushing syndrome: Undergoing or planning pregnancy (females only). Known allergy to Lignocaine. Adrenal cancer (post-operative histology diagnosis),cyclic Cushings, squamous cell lung carcinoma, bronchial carcinoid and occult ectopic Cushings. Concurrent use of steroid therapy for any other medical condition (oral, inhaled, parenteral or topical)
- Adrenal insufficiency: Undergoing or planning pregnancy, known allergy to Lignocaine, use of other steroid medications other than their standard glucocorticoid and fludrocortisone replacement, other interfering medication or diet within 2 weeks of sampling.
- CAH: Males, females undergoing or planning pregnancy, known allergy to Lignocaine, use of other steroid medications other than their standard glucocorticoid and fludrocortisone replacement or other interfering medication or diet within 2 weeks of sampling
- Primary hyperaldosteronism: Undergoing or planning pregnancy (females only), known allergy to Lidocaine, known adrenal failure and/or on steroid therapy (oral, inhaled, parenteral or topical), concurrent use of interfering medication ( i.e. specific interfering antihypertensive medication) or diet within 2-4 weeks of ultradian sampling
- GHD: Undergoing or planning pregnancy (females only) or known allergy to Lignocaine
- Acromegaly: Undergoing or planning pregnancy (females only), known allergy to Lignocaine treatment with somatostatin analogues and other interfering medication (e.g. oestrogens)
Trial locations and contacts
4 sites in 4 countries.
4 sites in 4 countries
About this study
Official title: Dynamic Hormone Diagnostics (Ultradian)
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary Hyperaldosteronism during conventional diagnostic and therapeutic follow-up.
The 27 hour monitoring by ULTRADIAN takes into account the rhythm of hormones throughout the day. It is hoped that this information may in the future improve and simplify diagnostic procedures. Follow-up of patients in endocrinology still remains difficult including clinical signs of over and under-treatment, questionnaires of quality of life and blood testing necessitating often retesting. Simplification of the diagnostic procedure by obtaining detailed knowledge about the rhythm of hormones may contribute to the improvement and individualization of treatment and may decrease morbidity and mortality of endocrine patients.
Read the detailed description
Microdialysis fluid will be collected from all participants using the ULTRADIAN dynamic diagnostics system. This is a 3-component collection system which can easily be attached to a belt and allows participants to continue with their normal everyday activities whilst undergoing sampling. The micro-fractions are minute, the volume would normally be by far too small to use with current immunoassays.
ULTRADIAN will overcome this hurdle by introducing two novel techniques; ultrasensitive liquid chromatography tandem mass spectroscopy (LCMS/MS) for steroid hormones, and the proximity extension assay (PEA®), which allows the simultaneous assay of up to 96 analytes in only 1 µL fluid.
The microdialysis sampling will be performed in addition to the conventional diagnostic sampling, and during normal follow-up of patients.
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency, Acromegaly, Primary Hyperaldosteronism
- Being tested
- 27 hour subcutaneous fluid sampling
- Keywords
- dynamic hormone diagnostics, adrenal insufficiency, congenital adrenal hyperplasia, primary hyperaldosteronism, cushing syndrome, growth hormone deficiency, acromegaly
- Medical subject headings
- Adrenal Insufficiency, Adrenal Hyperplasia, Congenital, Cushing Syndrome, Dwarfism, Pituitary, Acromegaly, Hyperaldosteronism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
27 hour subcutaneous fluid samplingOther
One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.
A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours).
| Study group | Role | What they receive |
|---|---|---|
| Healthy controls (HC) | Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels. Receives: Other: 27 hour subcutaneous fluid sampling | |
| Cushing syndrome (CS) | Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.
A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control
Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source). Receives: Other: 27 hour subcutaneous fluid sampling | |
| Adrenal insufficiency (AI) | Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.
Study subjects: Subjects with established primary (adrenal) AI Receives: Other: 27 hour subcutaneous fluid sampling | |
| Congenital adrenal hyperplasia (CAH) | Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.
Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy Receives: Other: 27 hour subcutaneous fluid sampling | |
| Primary hyperaldosteronism (PHA) | Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.
Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.
Study subjects: Subjects with suspected PHA. Receives: Other: 27 hour subcutaneous fluid sampling | |
| Growth hormone insufficiency (GHD) | Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.
Study subjects: Adult subjects with established clinical and biochemical GHD. Receives: Other: 27 hour subcutaneous fluid sampling | |
| Acromegaly (A) | Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.
Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria Receives: Other: 27 hour subcutaneous fluid sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
steroids
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
Measured: 27 hours
androgens
Physiological hormonal by sampling of 27h subcutaneous fluid to measure androgens
Measured: 27 hours
mineralocorticoids
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure mineralocorticoids
Measured: 27 hours
ACTH
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure ACTH
Measured: 27 hours
growth hormone
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
Measured: 27 hours
steroids in Addison disease
Hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
Measured: 27 hours
steroids in congenital adrenal hyperplasia
Hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
Measured: 27 hours
androgen in congenital adrenal hyperplasia
Hormonal curve by sampling of 27h subcutaneous fluid to measure androgens
Measured: 27 hours
growth hormone in acromegaly
Hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
Measured: 27 hours
growth hormone in growth hormone deficiency
Hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
Measured: 27 hours
mineralocorticoids in primary hyperaldosteronism
Hormonal curve by sampling of 27h subcutaneous fluid to measure mineralocorticoids
Measured: 27 hours
Secondary outcomes (5)
Intra-individual variability and the accuracy of steroids hormones
comparison of steroids levels in repetitive testing
Measured: 27 hours
Intra-individual variability and the accuracy of androgens
comparison of androgens levels in repetitive testing
Measured: 27 hours
Intra-individual variability and the accuracy of mineralocorticoids
comparison of mineralocorticoids levels in retesting by microdialysis
Measured: 27 hours
Intra-individual variability and the accuracy of growth hormone
comparison of growth hormone levels in retesting by microdialysis
Measured: 27 hours
Intra-individual variability and the accuracy of ACTH
comparison of ACTH levels in retesting by microdialysis
Measured: 27 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2016 (estimated)
- Study startOct 2016
- Primary completion14 Nov 2023
- Study completion14 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Adrenal InsufficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 528 participants (actual)
Sponsor and investigators
- Lead sponsor
- Haukeland University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska Institutet, University Hospitals Bristol and Weston NHS Foundation Trust, Evangelismos Hospital
- Responsible party
- Sponsor
- Investigators
- Stafford Lightman, Professor, Principal investigator, University of BristolSophie Bensing, MD phD, Principal investigator, Karolinska InstitutetStylianos Tsagarakis, Professor, Principal investigator, Evaggelismos Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02934399
- Sponsor's protocol ID
- REKno 2015/872
- Acronym
- ultradian
- Status last verified
- Aug 2020
- First submitted
- 12 Jan 2016
- Last updated
- 15 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Upton TJ, Zavala E, Methlie P, Kampe O, Tsagarakis S, Oksnes M, Bensing S, Vassiliadi DA, Grytaas MA, Botusan IR, Ueland G, Berinder K, Simunkova K, Balomenaki M, Margaritopoulos D, Henne N, Crossley R, Russell G, Husebye ES, Lightman SL. High-resolution daily profiles of tissue adrenal steroids by portable automated collection. Sci Transl Med. 2023 Jun 21;15(701):eadg8464. doi: 10.1126/scitranslmed.adg8464. Epub 2023 Jun 21.
PubMed 37343084
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dynamic Hormone Diagnostics (Ultradian)
- ClinicalTrials.gov ID
- NCT02934399
- Acronym / sponsor ID
- ultradian / REKno 2015/872
- Conditions
- Adrenal Insufficiency, Congenital Adrenal Hyperplasia, Cushing Syndrome, Growth Hormone Deficiency, Acromegaly, Primary Hyperaldosteronism
- Keywords
- dynamic hormone diagnostics, adrenal insufficiency, congenital adrenal hyperplasia, primary hyperaldosteronism, cushing syndrome, growth hormone deficiency, acromegaly
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 528 participants (actual)
- Lead sponsor
- Haukeland University HospitalUniversity, hospital or other
- Collaborators
- Karolinska Institutet, University Hospitals Bristol and Weston NHS Foundation Trust, Evangelismos Hospital
- Study start
- Oct 2016 (actual)
- Primary completion
- 14 Nov 2023 (actual)
- Study completion
- 14 Nov 2023 (actual)
- First posted
- 17 Oct 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will investigate 27 hour profiles of hormones in the subcutaneous tissue of healthy subjects and patients with Addison's, Congenital Adrenal Hyperplasia, Growth Hormone Deficiency, acromegaly, Cushings and Primary Hyperaldosteronism during conventional diagnostic and therapeutic follow-up.
The 27 hour monitoring by ULTRADIAN takes into account the rhythm of hormones throughout the day. It is hoped that this information may in the future improve and simplify diagnostic procedures. Follow-up of patients in endocrinology still remains difficult including clinical signs of over and under-treatment, questionnaires of quality of life and blood testing necessitating often retesting. Simplification of the diagnostic procedure by obtaining detailed knowledge about the rhythm of hormones may contribute to the improvement and individualization of treatment and may decrease morbidity and mortality of endocrine patients.
Detailed description
Microdialysis fluid will be collected from all participants using the ULTRADIAN dynamic diagnostics system. This is a 3-component collection system which can easily be attached to a belt and allows participants to continue with their normal everyday activities whilst undergoing sampling. The micro-fractions are minute, the volume would normally be by far too small to use with current immunoassays.
ULTRADIAN will overcome this hurdle by introducing two novel techniques; ultrasensitive liquid chromatography tandem mass spectroscopy (LCMS/MS) for steroid hormones, and the proximity extension assay (PEA®), which allows the simultaneous assay of up to 96 analytes in only 1 µL fluid.
The microdialysis sampling will be performed in addition to the conventional diagnostic sampling, and during normal follow-up of patients.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Healthy controls (HC) | – | Other: 27 hour subcutaneous fluid samplingDefinition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels. |
| Cushing syndrome (CS) | – | Other: 27 hour subcutaneous fluid samplingDiagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid. A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source). |
| Adrenal insufficiency (AI) | – | Other: 27 hour subcutaneous fluid samplingMonitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls. Study subjects: Subjects with established primary (adrenal) AI |
| Congenital adrenal hyperplasia (CAH) | – | Other: 27 hour subcutaneous fluid samplingMonitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls. Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy |
| Primary hyperaldosteronism (PHA) | – | Other: 27 hour subcutaneous fluid samplingDiagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue. Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls. Study subjects: Subjects with suspected PHA. |
| Growth hormone insufficiency (GHD) | – | Other: 27 hour subcutaneous fluid samplingDiagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid. Study subjects: Adult subjects with established clinical and biochemical GHD. |
| Acromegaly (A) | – | Other: 27 hour subcutaneous fluid samplingDiagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls. Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria |
Who may qualify
- Ages
- 18 to 68 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy Controls and patients with established Cushing syndrome, Adrenal Insufficiency, Congenital adrenal hyperplasia, Primary hyperaldosteronism, Acromegaly and Growth hormone deficiency
Key inclusion criteria (7 listed)
- Healthy male and female subjects aged 18-68 years, non-smokers or regular smokers of greater than 6 cigarettes a day, BMI 16-29
- Male and female Cushing's syndrome aged 18-68 years with biochemically confirmed based on cortisol and ACTH measurements, dexamethasone suppression test and 1 of the following positive investigations (24 hour urine cortisol, salivary/serum cortisol profile). Visible tumour in the pituitary and/or one of the following positive tests pointing to pituitary source for ACTH overproduction (bilateral petrosal sinus sampling, corticotropin releasing hormone test, high dose dexamethasone suppression test) or adrenal tumour considered fit for surgery. No contraceptives for 6 weeks prior to sampling (females only). Patients on medical therapy e.g. metyrapone for Cushings to have a 2 week washout off treatment prior to sampling
- Male and female aged 18 -68 years with biochemically confirmed adrenal insufficiency based on basal cortisol and ACTH measurements and/or Synacthen test +/- adrenal antibodies, and on oral hydrocortisone or cortisone acetate glucocorticoid replacement therapy
- Female aged 18-68 years with biochemically confirmed salt-wasting or simple virilising CAH based on 17OHP, cortisol, androgen, renin and ACTH measurements; disease causing mutation in CYP21A2 and/or synacthen testing.
- Male and female subjects aged 18 -68 years with biochemical confirmation of PHA based on a valid pathological aldosterone/renin ratio and non-suppressible aldosterone levels on one of the currently used confirmatory tests (saline/oral fludrocortisone test). Unilateral only - diagnostic CT and/or adrenal vein sampling
Key exclusion criteria (7 listed)
- Healthy controls undergoing or planning pregnancy or lactating women. Presence of any unstable pathological condition in past 3 months. On any regular prescribed medications (except contraception). Prior or current history of an endocrine disorder. Known allergy to Lignocaine, plasters. Current or past steroid therapies (oral, inhaled, parenteral or topical) or other interfering medication in last 3 months. Regular alcohol intake great then 26units of alcohol per week.Taking of any investigational drug within the past two months. Abuse of illicit drugs. Occasional smokers of cigarettes not able to abstain for sampling period or smoking less than 6 cigarettes a day. Needle phobia. Interfering diet/over the counter herbal remedies in last 14 days.
- Cushing syndrome: Undergoing or planning pregnancy (females only). Known allergy to Lignocaine. Adrenal cancer (post-operative histology diagnosis),cyclic Cushings, squamous cell lung carcinoma, bronchial carcinoid and occult ectopic Cushings. Concurrent use of steroid therapy for any other medical condition (oral, inhaled, parenteral or topical)
- Adrenal insufficiency: Undergoing or planning pregnancy, known allergy to Lignocaine, use of other steroid medications other than their standard glucocorticoid and fludrocortisone replacement, other interfering medication or diet within 2 weeks of sampling.
- CAH: Males, females undergoing or planning pregnancy, known allergy to Lignocaine, use of other steroid medications other than their standard glucocorticoid and fludrocortisone replacement or other interfering medication or diet within 2 weeks of sampling
- Primary hyperaldosteronism: Undergoing or planning pregnancy (females only), known allergy to Lidocaine, known adrenal failure and/or on steroid therapy (oral, inhaled, parenteral or topical), concurrent use of interfering medication ( i.e. specific interfering antihypertensive medication) or diet within 2-4 weeks of ultradian sampling
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 27 hour subcutaneous fluid samplingOne hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital. A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours). | Other | Acromegaly (A), Adrenal insufficiency (AI), Congenital adrenal hyperplasia (CAH), Cushing syndrome (CS), Growth hormone insufficiency (GHD), Healthy controls (HC), Primary hyperaldosteronism (PHA) |
Primary outcome
steroids
Time frame: 27 hours
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
androgens
Time frame: 27 hours
Physiological hormonal by sampling of 27h subcutaneous fluid to measure androgens
mineralocorticoids
Time frame: 27 hours
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure mineralocorticoids
ACTH
Time frame: 27 hours
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure ACTH
growth hormone
Time frame: 27 hours
Physiological hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
steroids in Addison disease
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
steroids in congenital adrenal hyperplasia
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure steroids
androgen in congenital adrenal hyperplasia
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure androgens
growth hormone in acromegaly
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
growth hormone in growth hormone deficiency
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure growth hormone
mineralocorticoids in primary hyperaldosteronism
Time frame: 27 hours
Hormonal curve by sampling of 27h subcutaneous fluid to measure mineralocorticoids
5 secondary outcomes
Intra-individual variability and the accuracy of steroids hormones
Time frame: 27 hours
Intra-individual variability and the accuracy of androgens
Time frame: 27 hours
Intra-individual variability and the accuracy of mineralocorticoids
Time frame: 27 hours
Intra-individual variability and the accuracy of growth hormone
Time frame: 27 hours
Intra-individual variability and the accuracy of ACTH
Time frame: 27 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2023.
- Derived from this study: PubMed 37343084Upton TJ, Zavala E, Methlie P, Kampe O, Tsagarakis S, Oksnes M, Bensing S, Vassiliadi DA, Grytaas MA, Botusan IR, Ueland G, Berinder K, Simunkova K, Balomenaki M, Margaritopoulos D, Henne N, Crossley R, Russell G, Husebye ES, Lightman SL. High-resolution daily profiles of tissue adrenal steroids by portable automated collection. Sci Transl Med. 2023 Jun 21;15(701):eadg8464. doi: 10.1126/scitranslmed.adg8464. Epub 2023 Jun 21.
- Individual participant dataSharing planned: No
Related trials for Adrenal Insufficiency
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingObservational study
Evaluation of Children With Endocrine and Metabolic-Related Conditions
Adrenal Insufficiency, Growth Disorder
Recruiting
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
Cushing Syndrome, Adrenal Insufficiency
RecruitingObservational study
Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids.
Reumatoid Arthritis, Corticosteroids Adverse Reaction
Recruiting
Home Exercise for Individuals With Neurodegenerative Disease
Neurodegenerative Diseases, Leukodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stafford Lightman, Professor principal investigator
University of Bristol
Sophie Bensing, MD phD principal investigator
Karolinska Institutet
Stylianos Tsagarakis, Professor principal investigator
Evaggelismos Hospital
4 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adrenal Insufficiency and Congenital Adrenal Hyperplasia, run by Haukeland University Hospital at 4 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Greece, Norway, Sweden, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
steroids (time frame: 27 hours). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02934399, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2023.